Evidence map›Paper›PMID 38434527›Full record

ArticleHemaSphere2024

Robust identification of conventional and leukemic nonnodal mantle cell lymphomas using epigenetic biomarkers.

Marco M Bühler, Marta Kulis, Martí Duran-Ferrer, Cristina López, Guillem Clot, Ferran Nadeu, Mònica Romo, Eva Giné, Armando López-Guillermo, Sílvia Beà and 2 more

Abstract read
In one paragraph

Article in HemaSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marco M BühlerInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.ORCID https://orcid.org/0000-0003-0850-3326
Marta KulisInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Martí Duran-FerrerInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Cristina LópezInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Guillem ClotInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Ferran NadeuInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Mònica RomoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Eva GinéInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Armando López-GuillermoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Sílvia BeàInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
Elías CampoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.
José Ignacio Martín-SuberoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain.ORCID 0000-0001-8809-5195

Funding

Preclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI INGHIRAMI, GIORGIO · 2018 to 2022
$10.2M
NCI NIH HHS P01 CA229100
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38434527
PMCPMC10878179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.